Drug intelligence / Profile preview

bendamustine + methotrexate + 5-fluorouracil

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Intravenous

Overview

Bendamustine + methotrexate + 5-fluorouracil (BMF) is a chemotherapy combination regimen where bendamustine replaces cyclophosphamide in the traditional CMF (cyclophosphamide, methotrexate, 5-fluorouracil) regimen. This combination has been studied primarily for metastatic breast cancer (MBC). In clinical trials, BMF demonstrated significantly longer time to progression compared to CMF (8.2 versus 6.7 months), particularly in patients with prior adjuvant therapy without visceral metastases. The overall response rates were similar between BMF (44%) and CMF (40%), though BMF caused more myelotoxicities, particularly leukopenia.

Targets

TS (Thymidylate synthase)DNADHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on bendamustine + methotrexate + 5-fluorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bendamustine + methotrexate + 5-fluorouracil.

Explore the full profile